Article

Morning stiffness for assessing RA: Utility varies with activity

The duration of morning stiffness in patients who have rheumatoid arthritis (RA) correlates better with other patient-reported outcomes than with joint counts and erythrocyte sedimentation rate (ESR).

The duration of morning stiffness in patients who have rheumatoid arthritis (RA) correlates better with other patient-reported outcomes than with joint counts and erythrocyte sedimentation rate (ESR). As an individual variable, morning stiffness duration has a moderate ability to differentiate active RA from inactive RA.

Khan and coworkers sought to determine whether assessing morning stiffness in the routine evaluation of patients with RA remains worthwhile, noting conflicting reports about the relationship between morning stiffness duration and active RA. They correlated the severity of morning stiffness with RA activity as assessed by the Disease Activity Score (DAS28). They also explored whether including morning stiffness duration in the Routine Assessment of Patient Index Data 3 (RAPID3) is useful. Information came from a database of 5439 patients in 24 countries.

Morning stiffness duration was moderately correlated with pain; general health; and Health Activity Questionnaire, RAPID3, and DAS28 scores. It was weakly correlated with fatigue, joint counts, and ESR. Morning stiffness duration varied among patients with different RA disease activity states.

The authors noted that morning stiffness is a complex symptom and that assessment of morning stiffness duration in patients with low RAPID3 scores may be clinically relevant.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.